SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Jang et al. (2024) in their original research, reported that among multiple (TDZs, ﻿SGLT2 blockers, dipeptidyl peptidase 4 (DPP-4) antagonists, and sulfonylureas) orally prescribed antidiabetic medication, SGLT2 antagonists possibly would somewhat better choice among patients with NAFLD and T2DM.